Toripalimab Combined With Definitive CCRT for LACC Patients

Summary

Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent/metastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1. Toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1, showed promising anti-tumor efficacy in multiple solid tumors. This randomised study is evaluating toripalimab combined with CCRT versus CCRT alone for treatment-naïve LACC.

Eligibility

Inclusion Criteria:

* more than 18 years old females
* had newly diagnosed and previously untreated locally advanced squamous cell carcinoma of the uterine cervix
* FIGO 2018 stage IB3 to IVA with no evidence of distant metastasis
* ECOG PS 0-1 without major organ failure
* signed informed consent voluntarily

Exclusion Criteria:

* previously suffered from immunodeficiency disorders
* had any condition that researchers believed to be associated with increased risk of treatment
* Previously received or currently receiving other PD-1 antibody treatments or other immunotherapies targeting PD-1/PD-L1

Conditions4

Interventions1

Related trials

• 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer — Mabwell (Shanghai) Bioscience Co., Ltd.
• 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer — Mabwell (Shanghai) Bioscience Co., Ltd.
• A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study — LaNova Medicines Zhejiang Co., Ltd.
• A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer — Henan Cancer Hospital
• A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors — LaNova Medicines Limited
• A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. — Advenchen Laboratories, LLC
• A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer — Shanghai Junshi Bioscience Co., Ltd.
• A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors — Shanghai Junshi Bioscience Co., Ltd.

Browse More Trials